Skip to main content
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance
News article29 September 2015European Medicines Agency1 min read

ADVANCE Code of Conduct for public consultation

The Accelerated Development of VAccine benefit-risk Collaboration in Europe

(ADVANCE) is a a public-private partnership supported by the Innovative Medicines Initiative in order to establish a scientific and transparent framework for the rapid monitoring of the benefits and risks of marketed vaccines. For this purpose, ADVANCE is developing a Good practice guidance with a Code of Conduct for the planning, initiation, design, conduct and reporting of observational studies in the field of vaccines. The Code of Conduct will also support interactions between different parties involved in studies on vaccines and provide confidence to health professionals and the public about the quality of their results.

ADVANCE has launched a public consultation of the draft Code of Conduct until 15th November 2015.


Related information:

» ADVANCE website 


Publication date
29 September 2015
European Medicines Agency